Rx Products
For more Rx Product News,
go to PharmacyTimes.com/
publications/issue.
MORE @
PHARMACY
TIMES.COM
SPIRIVA RESPIMAT
Marketed by: Boehringer Ingelheim
Pharmaceuticals, Inc
Indication: The FDA has expanded
the use of Spiriva Respimat (tiotro-
pium bromide inhalation spray)
to include long-term, once-daily
maintenance treatment of asthma
in patients 12 years and older. The
recommended dosage for this indi-
cation is 2 inhalations of 1.25 mcg
once daily.
Dosage Form: Inhalation spray: 1.25
mcg tiotropium per actuation with
the Spiriva Respimat inhaler; 2 actu-
ations equal 1 dose (2.5 mcg)
For More Information:
www.spiriva.com
HUMIRA
Marketed by: AbbVie, Inc
Indication: The FDA has expanded
the use of Humira (adalimumab) to
include treatment of moderate to
severe hidradenitis suppurativa, an
inflammatory skin disease. For other
indications and the recommended
dosing and administration, see the
full prescribing information.
Dosage Form: Injection ( see the full
prescribing information )
For More Information:
www.humira.com
FYCOMPA
Marketed by: Eisai, Inc
Indication: The FDA has expanded
the use of Fycompa (perampanel
hydrate) CIII, a noncompetitive
AMPA glutamate receptor antago-
nist, to include adjunctive therapy in
the treatment of primary general-
ized tonic-clonic seizures in patients
12 years or older with epilepsy. For
dosage and administration, see the
full prescribing information.
Dosage Form: Tablets: 2, 4, 6, 8, 10,
and 12 mg
For More Information:
www.Fycompa.com
Marketed by: Actavis Pharma, Inc
Indication: The FDA has approved
Vraylar, an atypical antipsychotic, for
the treatment of schizophrenia and
acute treatment of manic or mixed
episodes associated with bipolar I dis-
order. The recommended starting dose
for the treatment of schizophrenia or
bipolar mania is 1.5 mg/day.
Dosage Form: Capsules: 1.5, 3, 4.5, and
6 mg
For More Information:
www.allergan.com
Vraylar
December's
Hot
Rx
Product!
December 2015 PharmacyTimes.com 49